Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression

Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression

Source: 
CP Wire
snippet: 

Sage Therapeutics (NASDAQ: SAGE) announced on 6/12/2018 its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA).